The benefits of TRISENOX for APL patients
Treatment with TRISENOX
® (arsenic trioxide) injection has been shown to eliminate or reduce
the number of cancer cells in the body, even when initial chemotherapy treatments have failed.
Additionally, TRISENOX works with minimal chemotherapy-related side effects.
High rates of remission
In clinical trials, TRISENOX has delivered high rates of complete remission for acute
promyelocytic leukemia (APL) patients whose disease returned after, or did not respond to,
initial treatment. In one U.S. multicenter trial, 85% of these patients showed no evidence of
disease following treatment with TRISENOX.
1 In another study, 11 of 12 relapsed APL patients
(92%) achieved complete remission.
2
Tolerability
In clinical studies, TRISENOX has been generally well tolerated, with manageable and reversible
side effects. There was no incidence of hair loss, and few patients have had inflammation of
the mucous membranes, such as mouth sores, which may be more common with other cancer
medications.
When the serious symptoms of your APL have gone away, you may be able to be treated as an
outpatient. TRISENOX offers manageable administration schedules, with 1 to 2 hour intravenous
infusions. You will be in the office or clinic for about 2 to 3 hours for each treatment,
including about 1 hour for pre- and post-treatment examinations. If you experience flushing or
decreased blood pressure during treatment, the infusion may be slowed so that your dose is
given over as much as 4 hours.
>> Click here to learn more about dosing and administration for TRISENOX.
Serious adverse events, grade 3 or 4, were common. Those events attributable to TRISENOX in the
Phase 2 study of 40 patients with refractory or relapsed APL included APL differentiation
syndrome (n = 3), hyperleukocytosis (n = 3), QTc interval prolongation (n = 16), atrial
dysrhythmias (n = 2), hyperglycemia (n = 2), and torsades de pointes (n = 1).
1. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
2. Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.